Filings monitor · CVS

What CVS HEALTH Corp's SEC filings said

10-Q for 2026Q3, filed 4 Nov 2026, and 2 8-Ks since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Guidance and Outlook83 · importance in its document · 8-K exhibit · 4 Nov 2026
   CVS Health raised its full-year 2026 GAAP diluted EPS guidance to at least $6.98, from a range of $6.84 to $7.04, and Adjusted EPS guidance to at least $8.20, from $7.90 to $8.10. It raised cash flow from operations guidance to at least…
2. Cash Flow and Liquidity69 · importance in its document · 10-Q · 2026Q3
   Cash and cash equivalents totaled approximately $11.7 billion at September 30, 2026, including approximately $5.9 billion held by the parent company or nonrestricted subsidiaries. Nine-month operating cash flow rose $8.069 billion, or…
3. Strategic Business Separation65 · importance in its document · 10-Q · 2026Q3
   On November 4, 2026, CVS Health announced an intended separation into two independent, publicly traded companies in a transaction intended to be tax-free for U.S. federal income tax purposes. The healthcare solutions company will include…
4. Operating Income and Margins63 · importance in its document · 10-Q · 2026Q3
   Consolidated operating income was $12.949 billion for the nine months ended September 30, 2026, compared with $2.548 billion in 2025, an increase of $10.401 billion, or 408.2%; third-quarter operating income was $3.566 billion versus a…
5. Health Care Benefits Performance63 · importance in its document · 8-K exhibit · 4 Nov 2026
   Health Care Benefits third-quarter revenue increased 2.4% to $36.855 billion, primarily on Government business growth, partly offset by the company’s exit from the individual exchange business in 2026. Government premium revenue grew 8.2%…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 4 Nov 2026

Full report · Filing on EDGAR

• Cash Flow and LiquidityImportance 69
  Cash and cash equivalents totaled approximately $11.7 billion at September 30, 2026, including approximately $5.9 billion held by the parent company or nonrestricted subsidiaries. Nine-month operating cash flow rose…
• Strategic Business SeparationImportance 65
  On November 4, 2026, CVS Health announced an intended separation into two independent, publicly traded companies in a transaction intended to be tax-free for U.S. federal income tax purposes. The healthcare solutions…
• Operating Income and MarginsImportance 63 · +1 more on this subject
  Consolidated operating income was $12.949 billion for the nine months ended September 30, 2026, compared with $2.548 billion in 2025, an increase of $10.401 billion, or 408.2%; third-quarter operating income was $3.566…
• Segment Revenue PerformanceImportance 61 · +1 more on this subject
  Health Care Benefits’ nine-month Government premium revenue increased $7.585 billion, or 9.9%, to $84.385 billion, while Commercial premium revenue declined $4.836 billion, or 20.2%, to $19.095 billion. The Commercial…
• State Non-Income Tax ChangeImportance 48 · +1 more on this subject
  A retroactive change in a state law related to non-income taxes contributed to CVS Health’s increased adjusted operating loss for the nine months ended September 30, 2026. The filing does not identify the state, the…
• Health Services Pharmacy DemandImportance 42 · +1 more on this subject
  Health Services revenue grew 9.5% in the third quarter and 10.6% in the first nine months of 2026, primarily from pharmacy drug mix and brand inflation, partly offset by continued pharmacy client price improvements.…
• PBM Rebate and Pricing PressureImportance 38
  CVS continues to pass a larger portion of pharmaceutical manufacturer rebates, fees and discounts to clients and typically offers minimum pricing guarantees that it may not achieve. Manufacturers are also applying…
• Medical Cost Trend / Benefit RatioImportance 37
  Health Care Benefits’ medical benefit ratio (MBR) improved to 91.3% in the third quarter of 2026 from 92.8% a year earlier, a 150-basis-point decrease driven primarily by improved underlying Government business…
• PBM Legislative RestrictionsImportance 35
  The filing reports that legislation and regulations seeking comprehensive regulation of pharmacy benefit manager activities have been proposed or enacted in a majority of U.S. states and at the federal level. Some…
• Omnicare Litigation ResolutionImportance 34 · +1 more on this subject
  In the third quarter of 2026, CVS Health recorded an estimated contingent guarantee liability tied to agreements to resolve litigation and Chapter 11 bankruptcy matters involving Omnicare, LLC and certain subsidiaries.…
• Medicare Advantage Payment OutlookImportance 33
  On April 6, 2026, the U.S. Centers for Medicare & Medicaid Services issued final 2027 Medicare Advantage payment rates, which imply an average industry revenue increase of 2.48%, excluding CMS’s estimate of Medicare…
• DividendsImportance 27 · +1 more on this subject
  CVS declared a quarterly cash dividend of $0.665 per share in the three months ended September 30, 2026, unchanged from the prior-year quarter. Dividends declared totaled $1.995 per share in the nine months ended…

8-K filings last 12 months

• Press release attached to an 8-K4 Nov 2026 · 8-K
  Read from the attached exhibit: Strategic Business Separation
• Guidance raised4 Nov 2026 · 8-K Item 2.02 · Flagged · rule score 60
  “CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE”
  Read from the attached exhibit: Guidance and Outlook · Health Care Benefits Performance · Cash Flow and Liquidity
• Board change17 Aug 2026 · 8-K Item 5.02 · Routine · rule score 10
  “On August 13, 2026, Larry M. Robbins notified the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) of his resignation from the Board, effective immediately.”
• Results (release not read)5 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Debt and Capital Allocation · Guidance and Outlook · Operating Expense Trends
• Management change (filing not read)18 May 2026 · 8-K Item 5.02 · Routine · rule score 20
• Results (release not read)6 May 2026 · 8-K Item 2.02 · Routine · rule score 20
• Board change19 Mar 2026 · 8-K Item 5.02 · Routine · rule score 10
  “: On March 18, 2026, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected John E. Gallina to serve on the Board, effective March 19, 2026.”
• Results (release not read)10 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 5 Aug 2026
  Legacy Litigation Charges · Liquidity and Cash Position · Operating Income and Margins

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.